Twist Bioscience (NASDAQ:TWST – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11, MarketWatch Earnings reports. Twist Bioscience had a negative net margin of 88.97% and a negative return on equity of 29.09%. The business had revenue of $66.95 million during the quarter, compared to analyst estimates of $63.35 million. During the same quarter in the previous year, the business posted ($0.91) EPS. The company’s quarterly revenue was up 16.8% compared to the same quarter last year.
Twist Bioscience Stock Performance
NASDAQ:TWST opened at $23.60 on Friday. The company has a fifty day moving average of $18.65 and a two-hundred day moving average of $18.94. The stock has a market capitalization of $1.35 billion, a PE ratio of -6.08 and a beta of 1.32. Twist Bioscience has a fifty-two week low of $11.46 and a fifty-two week high of $31.51.
Hedge Funds Weigh In On Twist Bioscience
A number of large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its position in Twist Bioscience by 22.7% during the third quarter. Morgan Stanley now owns 1,117,737 shares of the company’s stock worth $22,645,000 after acquiring an additional 206,748 shares during the period. Mercer Global Advisors Inc. ADV raised its position in shares of Twist Bioscience by 109.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 22,300 shares of the company’s stock valued at $452,000 after buying an additional 11,655 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Twist Bioscience by 11.5% in the third quarter. The Manufacturers Life Insurance Company now owns 53,591 shares of the company’s stock valued at $1,086,000 after buying an additional 5,527 shares during the last quarter. Royal Bank of Canada raised its position in shares of Twist Bioscience by 24.3% in the third quarter. Royal Bank of Canada now owns 18,861 shares of the company’s stock valued at $382,000 after buying an additional 3,690 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Twist Bioscience by 1.0% in the third quarter. Northern Trust Corp now owns 554,256 shares of the company’s stock valued at $11,229,000 after buying an additional 5,472 shares during the last quarter.
Analysts Set New Price Targets
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- Five stocks we like better than Twist Bioscience
- What Are Dividend Achievers? An Introduction
- Williams-Sonoma is a steal for buy-and-hold investors
- What Does Downgrade Mean in Investing?
- A closer look at Warren Buffett’s latest surprise purchase
- What is the Dogs of the Dow Strategy? Overview and Examples
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.